Clover Biopharmaceuticals has begun a Phase II clinical trial to assess its Covid-19 vaccine candidate, SCB-2019 (CpG 1018/Alum), as a heterologous booster shot in people who received an initial vaccine regimen.

Using its Trimer-Tag technology platform, the company developed the SCB-2019 antigen, which was merged with CpG 1018 advanced adjuvant of Dynavax and aluminum hydroxide (alum).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The double-blind, controlled, randomised, two-stage trial is sponsored by the Instituto D’Or de Pesquisa e Ensino (IDOR) and has received funding from the Bill & Melinda Gates Foundation.

It is also being backed by the Brazilian Ministry of Health.

The investigator-led trial will assess the safety and immunogenicity of a booster dose of the protein-based vaccine in almost 520 healthy adult subjects at multiple trial centres in Brazil.

Its first stage will analyse three vaccine formulations given as a booster shot almost six months after the initial vaccine regimen with AstraZeneca-Fiocruz’s recombinant Covid-19 shot.

In the second stage, the immunogenicity and safety of a booster dose of the opted formulation of SCB-2019 will be analysed in people inoculated with two shots of either the CoronaVac vaccine or the AstraZeneca-Fiocruz vaccine.

The preliminary results from the trial are expected to be announced in the first half of next year.

Clover Biopharmaceuticals CEO Joshua Liang said: “We are excited to learn how our Covid-19 vaccine candidate performs as a booster dose for people previously vaccinated with either inactivated or adenovirus-vectored Covid-19 vaccines.

“SPECTRA trial data reported in September showed that vaccination with SCB-2019 (CpG 1018/Alum) in individuals previously infected by SARS-CoV-2 demonstrated a rapid and strong boosting effect on neutralising antibody titers, as well as a favourable safety profile, thus supporting the evaluation of our Covid-19 vaccine candidate as a potential booster vaccine.”

In June, Clover signed an advance purchase agreement with Gavi, the Vaccine Alliance, to deliver up to 414 million doses of the vaccine.